Breast cancer (BC) is the most diagnosed cancer in young women. Advances in treatment have significantly improved long-term outcomes. In modern societies, many women are delaying childbirth, leading to a growing number of BC survivors who want to have children after their treatment. Fertility concerns are crucial for young BC patients, impacting their treatment decisions and adherence. The treatment for early-stage BC is complex and includes various therapies such as chemotherapy, endocrine therapy, anti-HER2 therapies, immunotherapy, and targeted agents. All of these treatments carry the potential risk of damaging the ovaries and causing fertility issues, which need to be carefully evaluated. In this review, we will explore the risk of ovarian damage associated with BC treatments, including newer agents such as CDK4/6 and Poly (ADP-ribose) Polymerases (PARP) inhibitors, as well as immunotherapy, along with recommendations for an accurate assessment regarding the risk of gonadotoxicity.